Severe fatigue in the first year following SARS-CoV-2 infection: A prospective cohort study 5 163 Table S3b. Outcome redefined as fatigue since one month after illness onset Model 1 Model 2 Model 3 aOR (95% CI) p-value aOR (95% CI) p-value aOR (95% CI) p-value Age per 10 year increase, years 0.90 (0.70-1.17) 0.346 0.88 (0.69-1.13) 0.307 0.82 (0.62-1.06) 0.266 Sex 0.279 0.213 0.299 Male Ref. Ref. Ref. Female 1.50 (0.74-3.03) 1.57 (0.77-3.19) 1.60 (0.76-3.38) No. of highrisk COVID-19 comorbidities* 0.20 NA NA 0 Ref. NA NA 1 1.11 (0.44-2.77) NA NA 2 2.12 (0.67-6.68) NA NA 3+ 4.16 (1.25-13.8) NA NA COVID-19 clinical severity** NA 0.003 0.004 Mild NA Ref. Ref. Moderate NA 2.48 (1.01-6.06) 2.18 (0.86-5.53) Severe/critical NA 5.18 (1.73-15.5) 5.22 (1.68-16.2) Highest baseline sadness score*** NA NA 0.140 0-1 NA NA Ref. 2-5 NA NA 0.57 (0.22-1.48) 6-10 NA NA 1.95 (0.84-4.51) NA=Not applicable; RR=respiratory rate; SpO2= oxygen saturation. *COVID-related comorbidities are based on WHO Clinical Management Guidelines[16] and include: cardiovascular disease (including hypertension), chronic pulmonary disease (excluding asthma), renal disease, liver disease, cancer, immunosuppression (excluding HIV, including previous organ transplantation), previous psychiatric illness and dementia. **COVID-19 clinical severity groups defined as: mild as having a RR<20/min and SpO2on room air >94% at both day 0 and 7; moderate disease as having a RR 20-30/min, SpO290-94% and/or receiving oxygen therapy at day 0 or 7; severe disease as having a RR>30/min or SpO2< 90% at day 0 or 7; critical disease as requiring ICU admission. ***Highest baseline sadness scores defined as the highest reported level of sadness at D0 and D7 (baseline), subjectively reported on a scale from 0 to 10.
RkJQdWJsaXNoZXIy MTk4NDMw